GILD - ギリアド・サイエンシズ （Gilead Sciences Inc.） ギリアド・サイエンシズGILDのチャート
GILDの企業情報
| symbol | GILD |
|---|---|
| 会社名 | Gilead Sciences Inc （ギリアド・サイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ギリアド・サイエンシズ（Gilead Sciences Inc.）は医薬品の発見・開発・商業化を行う研究型バイオ医薬品会社である。同社の製品ポートフォリオと治験薬のパイプラインはヒト免疫不全ウイルス、後天性免疫不全症候群（HIV/AIDS）、肝疾患、癌、炎症、呼吸器疾患、心血管疾患を含む。HIV/AIDS患者用製品は「Descovy」、「Odefsey」、「Genvoya」、「Stribild」、「Complera」、「Eviplera」、「Truvada」、「Emtriva」、「Tybost」、「Vitekta｣を含む。肝臓疾患患者用製品は「Vemlidy」、「Epclusa」、「Harvoni」、「Sovaldi」、「Viread」、「Hepsera｣を含む。同社は血液学・腫瘍疾患の患者にZydeligを提供する。心臓血管疾患の患者用製品は「Letairis」、「Ranexa」、「Lexiscan｣を含む。炎症・呼吸器疾患治療用の製品は「Cayston」と「Tamiflu」を含む。 ギリアド・サイエンシズは米国の医薬品会社。主要製品は抗HIV薬の｢ツルバダ｣、｢アトリプラ｣、B型肝炎治療薬｢ヘプセラ｣、｢ビリア―ド｣、侵襲性真菌感染症治療薬｢アンビゾ―ム｣、肺動脈高血圧症治療薬｢レタイリス｣、サイトメガロウイルス性網膜炎治療薬｢ビスタイド｣、慢性狭心症治療薬｢ラネクサ｣など。本社はカリフォルニア州。 Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States. |
| 本社所在地 | 333 Lakeside Drive Foster City CA 94404 USA |
| 代表者氏名 | John C. Martin ジョンC.マーティン |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 650-574-3000 |
| 設立年月日 | 31929 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1992年 |
| 従業員数 | 10000人 |
| url | www.gilead.com |
| nasdaq_url | https://www.nasdaq.com/symbol/gild |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 11943 |
| 終値（lastsale） | 76.4 |
| 時価総額（marketcap） | 99040421305.2 |
| 時価総額 | 時価総額（百万ドル） 94982.88 |
| 売上高 | 売上高（百万ドル） 23197 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 98125.88 |
| 当期純利益 | 当期純利益（百万ドル） 7690 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Gilead Sciences Inc. revenues decreased 21% to $10.74B. Net income before extraordinary items decreased 42% to $3.35B. Revenues reflect Antiviral products segment decrease of 26% to $9.14B. Net income also reflects Research and development expenses increase of 19% to $2.13B (expense) Selling general and administrative expe increase of 13% to $1.98B (expense). |
GILDのテクニカル分析
GILDのニュース
Gilead Sciences Stock: Look Beyond Mediocre 2022 Guidance - Pharma Can Deliver When It Matters 2022/02/04 16:50:22 Seeking Alpha
Alphabet, Brinker International rise; PayPal, Gilead fall 2022/02/02 21:21:01 ABC News
Stocks that traded heavily or had substantial price changes Wednesday: Alphabet, Brinker International rise; PayPal, Gilead fall
Did Hedge Funds Get Gilead Sciences, Inc. (GILD) Right? 2022/02/02 20:25:44 Insider Monkey
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Global Immunotherapy Markets, 2021-2027: Growth Drivers Include Increasing Prevalence of Auto-Immune Diseases in Adults and Increasing Investments in Research and Funding of Cancer - ResearchAndMarkets.com 2022/02/02 14:35:00 Kwhen Finance
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales 2022/02/02 12:33:38 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus LogicBio Phase 1/2 Study Of Genome Editing Therapy In Methylmalonic Acidemia Placed On Clinical Hold LogicBio Therapeutics, Inc. (NASDAQ: LOGC ) announced the U.S. Food and Drug Administration has notified the company that its Phase 1/2 SUNRISE clinical trial of LB-001 in pediatric patients with methylmalonic acidemia has been placed on clinical hold. LB-001 is LogicBio''s investigational, single-administration, adeno-associated virus genome editing therapy. The company noted as reported earlier, the third patient dosed in the SUNRISE trial, who is in the younger age group of 6 months to 2 years old, experienced a drug-related serious adverse event, which was categorized as a case of thrombotic microangiopathy. The stock was sliding 16% to $1.26 in premarket trading. Click here to access Benzinga''s FDA Calendar Atea Announces Publication Of Positive Data On Investigational COVID-19 Treatment Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) announced the publication in the peer-reviewed journal "Nature Communications" new data demonstrating bemnifosbuvir''s unique mechanism of action that provides the potential to create a high barrier to resistance with broad antiviral activity across SARS-CoV-2 variants of concern.
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Recommendation of “Buy” by Analysts 2021/12/09 17:52:42 Transcript Daily
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been given an average rating of “Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month price target among […]
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Shoker Investment Counsel Inc. 2021/12/09 17:14:48 Transcript Daily
Shoker Investment Counsel Inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,837 shares of the biopharmaceutical companys stock after buying an additional 1,415 shares during the period. Shoker Investment Counsel Inc.s holdings []
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Howland Capital Management LLC 2021/12/09 16:36:44 Transcript Daily
Howland Capital Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,536 shares of the biopharmaceutical companys stock after selling 1,669 shares during the period. Howland Capital []
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Plimoth Trust Co. LLC 2021/12/09 13:38:42 Dakota Financial News
Plimoth Trust Co. LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,505 shares of the biopharmaceutical companys stock after selling 747 shares during the period. Plimoth Trust Co. LLCs holdings []
Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection 2021/12/09 13:30:00 Benzinga
Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV SAN FRANCISCO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR ) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating novel therapeutic combinations for the treatment of chronic hepatitis B virus (HBV) infection. The multi-arm trial, which is being conducted in collaboration with Gilead Sciences, Inc., is assessing various combinations of VIR-2218, Vir''s investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi); selgantolimod (GS-9688), Gilead Sciences'' investigational TLR-8 agonist; and nivolumab, an approved PD-1 inhibitor, in both nucleos(t)ide (NUC)-suppressed patients and viremic patients. Patients with HBV treatment experience also may receive tenofovir alafenamide fumarate (TAF). "For the majority of patients with chronic HBV, a functional cure will likely require a sustained reduction in hepatitis B surface antigen and restoration of the immune response," said Carey Hwang, MD, PhD, senior vice president, clinical research, head of chronic infection for Vir Biotechnology. "We believe the combination of VIR-2218 and two immunomodulatory agents has the potential to improve the HBV-specific immune response and possibly achieve a functional cure.